本文選題：替考拉寧　切入點：血液病　出處：《中華醫(yī)院感染學雜志》2015年18期

【摘要】：目的探討替考拉寧治療血液病患者革蘭陽性菌菌血癥的有效性和安全性,為臨床治療提供參考依據(jù)。方法回顧性分析2012年1月-2015年4月45例應用替考拉寧治療的血液病革蘭陽性菌菌血癥患者的臨床資料,所有患者均在血培養(yǎng)檢查后給予經(jīng)驗性抗感染治療,其中11例患者初始治療應用替考拉寧,34例患者血培養(yǎng)革蘭陽性菌感染加用替考拉寧治療,評價替考拉寧在治療中的療效和安全性;采用SPSS17.0統(tǒng)計軟件對數(shù)據(jù)進行統(tǒng)計分析。結果 45例患者中治愈21例、顯效18例,總有效率為86.7%;治療過程中發(fā)生不良反應2例,總不良反應發(fā)生率4.4%,均表現(xiàn)為皮疹,經(jīng)對癥治療后好轉;治療期間4例患者死亡,均因呼吸衰竭,1例治療過程中復查血培養(yǎng)替換為大腸埃希菌,2例分別合并大腸埃希菌和嗜麥芽寡養(yǎng)單胞菌感染;10例患者加用抗真菌治療后體溫降至正常。結論替考拉寧治療血液病患者革蘭陽性菌菌血癥療效確切,安全性高,但應重視病程中其他病原菌感染的可能。
[Abstract]:Objective to investigate the efficacy and safety of teicoplanin in the treatment of Gram-positive bacteremia in patients with hematologic diseases. Methods the clinical data of 45 patients with Gram-positive bacteremia of hematological diseases treated with teicoplanin from January 2012 to April 2015 were analyzed retrospectively. All the patients were treated with empirical anti-infective therapy after blood culture examination. Among them, 11 patients were treated with teicoplanin in the initial treatment and 34 patients were treated with teicoplanin plus teicoplanin for the infection of Gram-positive bacteria in blood culture. Results 21 cases were cured, 18 cases were effective, the total effective rate was 86.7%, and 2 cases had adverse reactions during the treatment, the efficacy and safety of teicoplanin in the treatment were evaluated, and the data were analyzed by SPSS17.0 statistical software, the results showed that 21 cases were cured, 18 cases were effective, and the total effective rate was 86.7%. The incidence of total adverse reactions was 4.4, all of them showed skin rash, improved after symptomatic treatment, and 4 patients died during the treatment. Blood culture was replaced by Escherichia coli in 2 patients with acute respiratory failure. 10 patients with infection of Escherichia coli and altotrophomonas maltophilia were treated with antifungal therapy, and their body temperature decreased to normal after antifungal therapy. Conclusion\\\. Coranine was effective in treating Gram-positive bacteremia in patients with hematologic diseases. Safety is high, but attention should be paid to the possible infection of other pathogens in the course of the disease.
【作者單位】： 鄭州大學第一附屬醫(yī)院血液科;
【基金】：國家自然科學基金資助項目(81000224)
【分類號】：R55;R515.3

【共引文獻】

相關期刊論文 前10條

1 薛峰;呂媛;;Mohnarin 2009年度報告:血標本來源的細菌耐藥監(jiān)測[J];中國臨床藥理學雜志;2011年05期

2 黃華艷;李蘭新;;重癥監(jiān)護室中心靜脈導管相關性感染分析[J];中國感染控制雜志;2012年05期

3 劉行超;莫姍;高云;曾桂芬;費燕楠;;血培養(yǎng)病原菌分布及耐藥性分析[J];國際檢驗醫(yī)學雜志;2013年02期

4 崔惠景;張芳;常軍霞;;血培養(yǎng)主要病原菌分布及耐藥性分析[J];國際檢驗醫(yī)學雜志;2013年07期

5 趙英妹;張玨;喬昀;;血培養(yǎng)陽性病原菌分布及耐藥性分析[J];國際檢驗醫(yī)學雜志;2013年07期

6 陳小晶;朱紅軍;柯永堅;黃江玲;肖亮生;;新生兒科與非新生兒病房血流感染病原菌比較[J];廣東醫(yī)學;2013年14期

7 周旋;陳曉霞;李雅君;曲惠紅;黃國璽;石鳳蘭;;回顧性分析醫(yī)院連續(xù)三年主要細菌耐藥情況的變化趨勢[J];貴陽中醫(yī)學院學報;2013年04期

8 王金鳳;常t，

本文編號：1683171